Abstract
Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.
| Original language | English |
|---|---|
| Pages (from-to) | 1837-1838 |
| Number of pages | 2 |
| Journal | Leukemia and Lymphoma |
| Volume | 46 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2005 |
Fingerprint
Keywords
- Multiple myeloma
- Neutropenia
- Septicemia
- Thalidomide
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. / Mazzotta, Serena; Gozzetti, Alessandro; Pirrotta, Maria Teresa; Bocchia, Monica; Sammassimo, Simona; Bucalossi, Alessandro; Lauria, Francesco.
In: Leukemia and Lymphoma, Vol. 46, No. 12, 12.2005, p. 1837-1838.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis
AU - Mazzotta, Serena
AU - Gozzetti, Alessandro
AU - Pirrotta, Maria Teresa
AU - Bocchia, Monica
AU - Sammassimo, Simona
AU - Bucalossi, Alessandro
AU - Lauria, Francesco
PY - 2005/12
Y1 - 2005/12
N2 - Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.
AB - Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.
KW - Multiple myeloma
KW - Neutropenia
KW - Septicemia
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=32144447592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32144447592&partnerID=8YFLogxK
U2 - 10.1080/10428190500237450
DO - 10.1080/10428190500237450
M3 - Article
C2 - 16263590
AN - SCOPUS:32144447592
VL - 46
SP - 1837
EP - 1838
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 12
ER -